Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

NHC

NHC Appoints Dr. Gifford and Mr. Adams to Board

National Healthcare Corporation (NYSE American: NHC) has recently appointed Dr. David Gifford and Mr. Andrew Adams to its board of directors. Dr. Gifford, a geriatrician and former chief medical officer of the American Health Care Association and the National Center for Assisted Living, brings a wealth of experience in serving older Americans. On the other hand, Mr. Adams, who previously served as the administrator of one of NHC's largest facilities, AdamsPlace, and has since overseen the expansion of a financial services company, brings expertise in long-term care administration and business operations.

NHC, a leading provider of long-term care healthcare services, operates 80 skilled nursing facilities with 10,329 beds, 26 assisted living communities with 1,413 units, nine independent living communities with 777 units, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies. Additionally, the company provides Alzheimer's and memory care units, pharmacy services, rehabilitation services, and management and accounting services to third-party post-acute operators.

It's worth noting that NHC's financial services company, led by Mr. Adams, has expanded from nine to twenty retail locations since 2014.

The addition of Dr. Gifford and Mr. Adams to the board of directors is expected to enhance the board's expertise in business and delivery models, with a continued focus on patient care. This move demonstrates NHC's commitment to strengthening its leadership team with individuals who bring diverse and extensive experience in the healthcare and long-term care sectors. Today the company's shares have moved -1.34% to a price of $137.15. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS